Stocktoria
Valneva SE VLA.PA
FR · Euronext Paris · XPAR · stock · Healthcare · website
Valneva SE financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €174.7M | €169.6M | €153.7M | €361.3M |
| Gross profit | €67.5M | €71.0M | €52.8M | €36.9M |
| R&D expense | €85.3M | €74.1M | €59.9M | €104.9M |
| SG&A expense | €74.7M | €95.1M | €96.6M | €57.6M |
| Operating income | -€81.6M | -€77.8M | -€82.1M | -€113.4M |
| Interest expense | €41.9M | €24.0M | €23.3M | €19.1M |
| Income tax | €1.1M | €761,000 | €2.8M | -€1.5M |
| Net income | -€115.2M | -€12.2M | -€101.4M | -€143.3M |
| EPS (diluted) | €-0.68 | €-0.08 | €-0.73 | €-1.24 |
| Operating cash flow | -€52.9M | -€67.2M | -€202.7M | -€245.3M |
| Free cash flow | -€57.4M | -€83.7M | -€217.1M | -€274.7M |
| Cash & equivalents | €109.7M | €168.3M | €126.1M | €286.5M |
| Inventory | €50.2M | €53.7M | €44.5M | €35.1M |
| Total assets | €398.8M | €500.0M | €460.1M | €621.3M |
| Total debt | €207.2M | €216.3M | €208.8M | €152.4M |
| Total liabilities | €292.7M | €318.8M | €331.8M | €401.5M |
| Shareholders' equity | €106.2M | €181.3M | €128.2M | €219.8M |
| Share buybacks | — | — | €240,000 | — |
Growth · year-over-year · Revenue CAGR -21.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +3.0% | +10.3% | -57.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · FR · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.